Long-term outcomes in juvenile idiopathi...
Long-term outcomes in juvenile idiopathic arthritis: Eighteen Years of Follow-Up in the Population-Based Nordic Juvenile Idiopathic Arthritis Cohort
https://doi.org/10.1002/acr.23853
Sustained Long-Term Efficacy of Motivational Counseling and Text Message Reminders on Daily Sitting Time in Patients With Rheumatoid Arthritis: Long-term follow-up of a randomized, parallel-group trial
Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early Rheumatoid Arthritis With Poor Prognosis
Sex Differences in the Achievement of Remission and Low Disease Activity in Rheumatoid Arthritis
Growth and puberty in juvenile dermatomyositis: a longitudinal cohort study
Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort
Long-term Outcomes of Temporomandibular Joints in Juvenile Idiopathic Arthritis: 17 Years of Followup of a Nordic Juvenile Idiopathic Arthritis Cohort
Complement lectin pathway protein levels reflect disease activity in juvenile idiopathic arthritis: a longitudinal study of the Nordic JIA cohort
Early Self-Reported Pain in Juvenile Idiopathic Arthritis as Related to Long-Term Outcomes: Results From the Nordic Juvenile Idiopathic Arthritis Cohort Study
Participation in school and physical education in juvenile idiopathic arthritis in a Nordic long-term cohort study
Mia Glerup
Veronika Rypdal
Ellen Dalen Arnstad
Maria Ekelund
Suvi Peltoniemi
Kristiina Aalto
Marite Rygg
Peter Toftedal
Susan Nielsen
Anders Fasth
Lillemor Berntson
Ellen Nordal
Troels Herlin
Nordic Study Group of Pediatric Rheumatology (NoSPeR)
Department of Paediatrics and Adolescent Medicine, Juliane Marie Centre
OBJECTIVE: The present study was undertaken to assess the long-term course, remission rate, and disease burden in juvenile idiopathic arthritis (JIA) 18 years after disease onset in a population-based setting from the early biologic era.
METHODS: A total of 510 consecutive cases of JIA with disease onset between 1997 and 2000 from defined geographic regions in Denmark, Norway, Sweden, and Finland were prospectively included in this 18-year cohort study. At the follow-up visit, patient-reported demographic and clinical data were collected.
RESULTS: The study included 434 (85%) of the 510 eligible JIA participants. The mean ± SD age was 24.0 ± 4.4 years. The median juvenile arthritis disease activity score in 71 joints (JADAS-71) was 1.5 (interquartile range [IQR] 0-5), with the enthesitis-related arthritis (ERA) category of JIA having the highest median score (4.5 [IQR 1.5-8.5], P = 0.003). In this cohort, 46% of patients still had active disease, and 66 (15%) were treated with synthetic disease-modifying antirheumatic drugs and 84 (19%) with biologics. Inactive disease indicated by a JADAS-71 score of <1 was seen in 48% of participants. Clinical remission off medication (CR) was documented in 33% of the participants with high variability among the JIA categories. CR was most often seen in persistent oligoarticular and systemic arthritis and least often in ERA (P < 0.001).
CONCLUSION: A substantial proportion of the JIA cohort did not achieve CR despite new treatment options during the study period. The ERA category showed the worst outcomes, and in general there is still a high burden of disease in adulthood for JIA.
Published - Apr 2020
© 2019, American College of Rheumatology.